Literature DB >> 16328406

Treatment of recurrent respiratory papillomatosis with microsurgery in combination with intralesional cidofovir--a prospective study.

Frederik G Dikkers1.   

Abstract

Recurrent respiratory papillomatosis (RRP) is an uncommon disease that may cause symptoms ranging from hoarseness to severe obstruction of the airway. Several treatment modalities have been tried, all with varying success. The goal of this study is to assess the benefit of the intralesional injection of cidofovir as an adjunct to microsurgical excision in treatment of laryngeal papillomatosis. All patients with RRP who presented between 1999 and 2004 at the University Medical Center Groningen were prospectively analyzed, regardless of the patients' age at presentation or duration of the disease. Not all patients were treated with cidofovir. To be included, all patients required a history of repeated microsurgery because of severe recurrence of RRP or because of severe technical difficulties in excising or vaporizing the lesion. Local microsurgery was performed, and then cidofovir, 2.5 mg/ml, was injected intralesionally. Treatment was repeated after 6, 12, 18, 24 and 30 weeks. Six male and three female patients were treated with cidofovir. Localization was the glottis in seven and the technically inaccessible dorsum epiglottidis and subglottis in one case each. The seven patients with glottic localization were cured. The two other patients showed recurrences, but at a lower rate than previously. Several times, however, more than six procedures were necessary. Cumulative doses of cidofovir ranged from 10.5 to 128 mg per patient. Cidofovir is a promising and powerful therapeutic approach for the treatment of RRP. Currently, the combination of microsurgery with intralesional cidofovir seems to be the treatment of choice for RRP.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16328406     DOI: 10.1007/s00405-005-1013-3

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  10 in total

1.  A staging system for assessing severity of disease and response to therapy in recurrent respiratory papillomatosis.

Authors:  C S Derkay; D J Malis; G Zalzal; B J Wiatrak; H K Kashima; M D Coltrera
Journal:  Laryngoscope       Date:  1998-06       Impact factor: 3.325

2.  Difficult tracheal intubation in obstetrics.

Authors:  R S Cormack; J Lehane
Journal:  Anaesthesia       Date:  1984-11       Impact factor: 6.955

Review 3.  Recurrent respiratory papillomatosis.

Authors:  C S Derkay
Journal:  Laryngoscope       Date:  2001-01       Impact factor: 3.325

4.  Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine].

Authors:  R Snoeck; W Wellens; C Desloovere; M Van Ranst; L Naesens; E De Clercq; L Feenstra
Journal:  J Med Virol       Date:  1998-03       Impact factor: 2.327

5.  Long-term follow-up of pediatric recurrent respiratory papillomatosis managed with intralesional cidofovir.

Authors:  Seth M Pransky; James T Albright; Anthony E Magit
Journal:  Laryngoscope       Date:  2003-09       Impact factor: 3.325

6.  [Intralesional cidofovir injections for recurrent laryngeal papillomatosis: first results].

Authors:  K Neumann; A Pudszuhn; C Welzel; S Bartel-Friedrich; M Passmann
Journal:  Laryngorhinootologie       Date:  2003-10       Impact factor: 1.057

7.  American Society of Pediatric Otolaryngology members' experience with recurrent respiratory papillomatosis and the use of adjuvant therapy.

Authors:  Scott Schraff; Craig S Derkay; Bonnie Burke; Louise Lawson
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2004-09

8.  Intralesional cidofovir and surgical excision for laryngeal papillomatosis.

Authors:  Ana Nusa Naiman; Philip Ceruse; Bruno Coulombeau; Patrick Froehlich
Journal:  Laryngoscope       Date:  2003-12       Impact factor: 3.325

9.  Cidofovir plasma assays after local injection in respiratory papillomatosis.

Authors:  Ana Nusa Naiman; Gilles Roger; Marie-Claude Gagnieu; Joelle Bordenave; Savine Mathaut; Sonia Ayari; Richard Nicollas; Jean-Baptiste Bour; Noel Garabedian; Patrick Froehlich
Journal:  Laryngoscope       Date:  2004-07       Impact factor: 3.325

10.  Intralesional cidofovir therapy for laryngeal papilloma in an adult cohort.

Authors:  Steven Bielamowicz; Vicente Villagomez; Sheila V Stager; William R Wilson
Journal:  Laryngoscope       Date:  2002-04       Impact factor: 3.325

  10 in total
  15 in total

1.  The clinical course of recurrent respiratory papillomatosis after the use of cidofovir is influenced by multiple factors.

Authors:  Michel R M San Giorgi; Robin E A Tjon Pian Gi; Frederik G Dikkers
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-10-29       Impact factor: 2.503

2.  Use of cidofovir in HPV patients with recurrent respiratory papillomatosis.

Authors:  M Grasso; M Remacle; V Bachy; S Van Der Vorst; G Lawson
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-04-23       Impact factor: 2.503

3.  Expression of matrix metalloproteinases (MMP-2 and MMP-9) in recurrent respiratory papillomas and laryngeal carcinoma: clinical and morphological parallels.

Authors:  Virgilijus Uloza; Vykintas Liutkevičius; Dalia Pangonytė; Viktoras Saferis; Vaiva Lesauskaitė
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-01-23       Impact factor: 2.503

4.  Experience of 11 years use of cidofovir in recurrent respiratory papillomatosis.

Authors:  M Graupp; M Gugatschka; K Kiesler; E Reckenzaun; G Hammer; G Friedrich
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-10-16       Impact factor: 2.503

5.  Safety of intralesional cidofovir in patients with recurrent respiratory papillomatosis: an international retrospective study on 635 RRP patients.

Authors:  R E A Tjon Pian Gi; T Ilmarinen; E R van den Heuvel; L M Aaltonen; J Andersen; J W Brunings; M Chirila; A Dietz; F Ferran Vilà; G Friedrich; H H W de Gier; W Golusinski; M Graupp; A Hantzakos; R Horcasitas; J Jackowska; J C Koelmel; G Lawson; F Lindner; M Remacle; C Sittel; V Weichbold; M Wierzbicka; F G Dikkers
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-02-03       Impact factor: 2.503

6.  Surgery and topic cidofovir for nasal squamous papillomatosis in HIV+ patient.

Authors:  Pasquale Capaccio; Francesco Ottaviani; Valeria Cuccarini; Mario Corbellino; Carlo Parravicini; Stefano Menzo; Antonio Schindler; Lorenzo Pignataro
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-07-22       Impact factor: 2.503

7.  Effectiveness of cidofovir intralesional treatment in recurrent respiratory papillomatosis.

Authors:  Małgorzata Wierzbicka; Joanna Jackowska; Anna Bartochowska; Agata Józefiak; Witold Szyfter; Witold Kędzia
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-04-26       Impact factor: 2.503

8.  Treatment of recurrent respiratory papillomatosis and adverse reactions following off-label use of cidofovir (Vistide®).

Authors:  Robin E A Tjon Pian Gi; Andreas Dietz; Vojko Djukic; Hans E Eckel; Gerhard Friedrich; Wojciech Golusinski; Anastasios Hantzakos; George Lawson; Marc Remacle; Heikki Rihkanen; Frederik G Dikkers
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-10-22       Impact factor: 2.503

Review 9.  Side-effects of cidofovir in the treatment of recurrent respiratory papillomatosis.

Authors:  Ferdinand I Broekema; Frederik G Dikkers
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-05-06       Impact factor: 2.503

Review 10.  Diagnostic and therapeutic pitfalls in benign vocal fold diseases.

Authors:  Jörg Bohlender
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2013-12-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.